Table 3.
Summary results for sarilumab 200 mg q2w combination vs other DMARD combinations in the csDMARD-IR population: median estimates of relative treatment effects (95% credible intervals) (base case) for week 24 efficacy and week 52 mTSS and safety (SI, SAE)
| Sarilumab 200 mg+csDMARD combination vs | ACR20 OR rREM (DIC=671.68) |
ACR50 OR rREM (DIC=632.99) |
ACR70 OR rREM (DIC=560.94) |
DAS28<2.6 OR rREM (DIC=427.34) | HAQ CFB diff REM (DIC=–133.71) |
mTSS 24 week CFB diff FEM (DIC=49.51) | mTSS 52 week CFB diff FEM (DIC=17.72) | SI 52 week RD REM (DIC=–44.23) |
SAE 52 week OR REM (DIC=140.50) |
| csDMARDs+placebo |
4.45
(2.43 to 8.25) |
5.14
(2.82 to 9.7) |
7.32
(3.03 to 20.69) |
7.88
(4.35 to 15.81) |
–0.25
(–0.36 to –0.141) |
–1.091
(–1.601 to –0.575) |
–2.53
(–3.42 to –1.65) |
0.012 (–0.151 to 0.178) |
2.31 (0.57 to 9.46) |
| csDMARDs+: | |||||||||
| Abatacept | 1.04 (0.52 to 2.03) |
1.14 (0.58 to 2.25) |
1.15 (0.43 to 3.29) |
1.37 (0.67 to 2.94) |
0.01 (–0.156 to 0.177) |
– | –0.13 (–1.73 to 1.44) |
0.004 (–0.178 to 0.202) |
2.61 (0.56 to 13.63) |
| Baricitinib 2 mg | 1.38 (0.61 to 3.15) |
1.56 (0.7 to 3.6) |
1.21 (0.39 to 4.19) |
1.33 (0.63 to 3.15) |
–0.003 (–0.181 to 0.175) |
–0.721
(–1.353 to –0.087) |
– | – | – |
| Baricitinib 4 mg | 0.9 (0.43 to 1.87) |
0.97 (0.46 to 1.95) |
0.83 (0.28 to 2.4) |
0.97 (0.48 to 2.04) |
0.053 (–0.11 to 0.219) |
–0.541 (–1.236 to 0.155) |
– | – | – |
| Tofacitinib | 1.69 (0.85 to 3.36) |
1.3 (0.66 to 2.66) |
1.07 (0.38 to 3.42) |
2 (0.94 to 4.71) |
0.037 (–0.102 to 0.177) |
–0.739
(–1.357 to –0.122) |
– | – | – |
| Adalimumab | 1.26 (0.66 to 2.42) |
1.17 (0.61 to 2.24) |
1.28 (0.5 to 3.55) |
1.27 (0.66 to 2.94) |
0.016 (–0.12 to 0.144) |
–0.082 (–0.848 to 0.684) |
0.07 (–1.39 to 1.49) |
–0.017 (–0.221 to 0.192) |
2.91 (0.37 to 26.5) |
| Certolizumab | 1.23 (0.58 to 2.68) |
1.18 (0.57 to 2.66) |
1.28 (0.44 to 4.75) |
1.24 (0.49 to 3.22) |
0.066 (–0.073 to 0.198) |
–0.906
(–1.637 to –0.178) |
–0.14 (–1.54 to 1.26) |
–0.018 (–0.250 to 0.212) |
1.02 (0.13 to 7.78) |
| Etanercept | 0.64 (0.24 to 1.67) |
0.7 (0.26 to 1.83) |
0.61 (0.09 to 2.99) |
0.4 (0.15 to 1.03) |
0.204 (–0.181 to 0.604) |
– | –1.24 (–3.09 to 0.63) |
– | – |
| Golimumab | 1.19 (0.59 to 2.37) |
1.39 (0.7 to 2.84) |
1.29 (0.48 to 4.03) |
1.43 (0.72 to 2.94) |
0.088 (–0.045 to 0.22) |
0.011 (–0.676 to 0.706) |
– | – | – |
| Infliximab | 1.41 (0.7 to 2.88) |
1.4 (0.67 to 3.01) |
1.3 (0.44 to 3.93) |
1.39 (0.67 to 3) |
0.165 (–1.451 to 1.907) |
– | – | –0.021 (–0.219 to 0.198) |
2.03 (0.35 to 12.43) |
| Tocilizumab 4 mg/kg intravenously | 1.93 (0.92 to 4.1) |
1.81 (0.87 to 3.96) |
1.8 (0.61 to 6.44) |
1.31 (0.58 to 3.14) |
–0.052 (–0.22 to 0.115) |
– | – | – | – |
| Tocilizumab 8 mg/kg intravenously | 1.48 (0.75 to 2.94) |
1.25 (0.64 to 2.57) |
1.18 (0.44 to 3.8) |
0.54 (0.26 to 1.19) |
–0.003 (–0.153 to 0.142) |
– | – | – | – |
| Tocilizumab SC 162 mg q1w | 1.63 (0.66 to 4.09) |
1.3 (0.54 to 3.37) |
1.37 (0.38 to 6.21) |
0.49 (0.2 to 1.34) |
– | – | – | – | – |
| Tocilizumab SC 162 mg q2w | 1.24 (0.53 to 2.93) |
1.07 (0.46 to 2.61) |
1.16 (0.34 to 4.32) |
0.64 (0.25 to 1.7) |
– | –0.477 (–1.182 to 0.223) |
– | – | – |
| Rituximab | 1.58 (0.78 to 3.16) |
1.65 (0.82 to 3.41) |
1.63 (0.57 to 5) |
2.32 (0.73 to 7.42) |
0.048 (–0.2 to 0.3) |
– | – | –0.037 (–0.276 to 0.200) |
2.57 (0.38 to 18.05) |
| Sarilumab 150 mg | 1.440 (0.76 to 2.69) |
1.43 (0.77 to 2.68) |
1.34 (0.54 to 3.33) |
1.35 (0.73 to 2.48) |
–0.01 (–0.119 to 0.098) |
–0.41 (–0.828 to 0.008) |
–0.65
(–1.29 to –0.01) |
0.010 (–0.153 to 0.174) |
1.26 (0.32 to 5.00) |
Models: ACR response and DAS28<2.6 using network meta-analyses with baseline risk rREM; HAQ using CFB with REM; Van der Heijde mTSS using mean CFB with FEM; SI using RD with REM; SAEs using logit model (OR) with REM; Italic text: in favour of sarilumab 200 mg combination; roman text: two treatment options are comparable.
ACR, American College of Rheumatology; CFB, change from baseline; DAS, Disease Activity Score; DIC, deviance information criterion; FEM, fixed-effects model; HAQ-DI, Health Assessment Questionnaire Disability Index; IR, inadequate response; MTX, methotrexate; RD, risk difference; SAEs, serious adverse events; SC, subcutaneous; SI, serious infections; csDMARD, conventional disease-modifying antirheumatic drugs; diff, difference; mTSS, modified total sharp score; rRAM, regression with random effects model.